Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results – OrthoSpineNews

CANTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for its third quarter ended September 30, 2019.

Third Quarter 2019 Financial Summary:

Third Quarter 2019 and Recent Highlights:

We delivered another quarter of significant year-over-year revenue growth across both our Advanced Wound Care and Surgical and Sports Medicine portfolios, said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. We grew our customer base across both portfolios and leveraged PuraPlys pass through advantage to gain new accounts, drive PuraPly adoption deeper into existing accounts and drive sales of our non-PuraPly products to existing PuraPly accounts. Strong execution also drove year-over-year growth of commercially available non-PuraPly products across our customer base. I am very pleased that despite amniotic capacity constraints, we successfully leveraged our diversified portfolio to deliver a solid quarter.

Mr. Gillheeney, Sr. continued: With continued execution against our PuraPly commercial strategy and improved amniotic capacity exiting Q3, we expect a strong finish to the year. We have updated our full-year 2019 revenue guidance and now expect to grow in a range of 31% to 34%. We remain committed to delivering on our mission to provide integrated healing solutions that substantially improve medical outcomes while lowering the overall cost of care.

READ THE REST HERE

More:
Organogenesis Holdings Inc. Reports Third Quarter and Nine Months of 2019 Financial Results - OrthoSpineNews